





PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

08 API: 27

Applicant's or agent's file reference C1-A0220P FOR FURTHER ACTION See Notification of Transmittal of Preliminary Examination Report (Form PC)							
International application No.	International filing date (day/month/year)		Priority date (day/month/year)				
PCT/JP2003/013063	10 October 2003 (10.	10.2003)	11 October 2002 (11.10.2002)				
International Patent Classification (IPC) or national classification and IPC C07K 16/18, C12P 21/08, A61K 39/395, A61P 35/00, 37/02, 43/00							
Applicant CHUGAI SEIYAKU KABUSHIKI KAISHA							
 This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36. 							
2. This REPORT consists of a total of	4 sheets, include	ling this cover	sheet,				
This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).							
These annexes consist of a total of sheets.							
3. This report contains indications rela	ating to the following items:						
I Basis of the report							
II Priority	П Priority						
III Non-establishment	of opinion with regard to nove	elty, inventive s	tep and industrial applicability				
IV Lack of unity of in	vention						
V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement							
VI Certain documents	VI Certain documents cited						
VII Certain defects in the international application							
VIII Certain observations on the international application							
VIII (
Date of submission of the demand	Date	of completion	of this report				
10 October 2003 (10.1	0.2003)	06	February 204 (06.02.204)				
Name and mailing address of the IPEA/JP		Authorized officer					
Facsimile No.	Tele	phone No.					

COPY SUBMITTED IN IDS



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/JP2003/013063

L. Basis of the report				
1. With	egard to the elements of the international application:*			
\boxtimes	the international application as originally filed			
П	the description:			
	pages, as originally filed			
	pages, filed with the demand			
	pages, filed with the letter of			
	the claims:			
	as originally filed			
	pages, as originally incompages, as amended (together with any statement under Article 19			
	pages, filed with the demand pages, filed with the letter of			
_				
	the drawings: pages , as originally filed			
	pages, filed with the demand			
	pages, filed with the letter of			
	he sequence listing part of the description:			
	pages, as originally filed			
	pages, filed with the demand			
	pages, filed with the letter of			
the i	regard to the language, all the elements marked above were available or furnished to this Authority in the language in which aternational application was filed, unless otherwise indicated under this item. e elements were available or furnished to this Authority in the following language which is:			
▎ٰ	the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).			
	the language of publication of the international application (under Rule 48.3(b)).			
	the language of the translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).			
3. With preli	regard to any nucleotide and/or amino acld sequence disclosed in the international application, the international minary examination was carried out on the basis of the sequence listing:			
	contained in the international application in written form.			
	filed together with the international application in computer readable form.			
	furnished subsequently to this Authority in written form.			
	furnished subsequently to this Authority in computer readable form.			
	The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.			
	The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.			
4.	The amendments have resulted in the cancellation of:			
	the description, pages			
	the claims, Nos			
	the drawings, sheets/fig			
5.	This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**			
in the	acement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to is report as "originally filed" and are not annexed to this report since they do not contain amendments (Rule 70.16 70.17). The properties of the containing such amendments must be referred to under item 1 and annexed to this report.			
Any	replacement sheel containing such amenaments must be rejerred to ander hem I and annexed to this report.			

COPY SUBMITTED IN IDS

INTERNATIONAL PRED MINARY EXAMINATION REPORT

Intern	application No.
PCT/JP	03/13063

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1.	Statement			
	Novelty (N)	Claims	4-23	YES
		Claims	1-3	NO
	Inventive step (IS)	Claims	5-23	YES
		Claims	1-4	NO
	Industrial applicability (IA)	Claims	1-23	YES
		Claims		NO

2. Citations and explanations

Document 1: Blood, 1997, Vol. 90, No. 9, pp. 3629-3639

Document 2: J. Exp. Med., 1995, Vol. 181, No. 6, pp.

2007-2015

Document 3: Int. Immunol., 1998, Vol. 10, No. 9, pp.

1347-1358

Document 4: Mol. Immunol., 1999, Vol. 36, No. 6, pp.

387-395

Document 5: Biochem. Biophys. Res. Commun., 1999, Vol.

258, No. 3, pp. 583-591

Document 6: Blood, 1999, Vol. 93, No. 11, pp. 3922-3930

Claims 1 to 3


Claims 1 to 3 lack novelty and do not involve an inventive step in the light of documents 1 to 3 cited in the international search report.

Document 1 indicates monovalent Fab' fragments from an antibody against the $\alpha 1$ domain of HLA class IA molecules from humans. Therefore, the invention that is indicated in document 1 cannot be differentiated from the invention that is set forth in claims 1 to 3 of the present application.

Document 2 indicates Fab fragments from the antibody (RE2) against the $\alpha 2$ domain of HLA class IA molecules from mice. Therefore, the invention that is indicated in

COPY SUBMITTED IN IDS

INTERNATIONAL PRELIMINARY EXAMINATION REPORT



document 2 cannot be differentiated from the invention that is set forth in claims 1 to 3 of the present application.

Document 3 indicates monovalent Fab fragments from an antibody against the $\alpha 3$ domain of HLA class IA molecules. Therefore, the invention that is indicated in document 3 cannot be differentiated from the invention that is set forth in claims 1 to 3 of the present application.

Claims 1 to 4

Claims 1 to 4 do not involve an inventive step in the light of documents 4 to 6 cited in the international search report. Documents 4 to 6 indicate the production of humanized antibodies from anti-HM1.24 antibodies that are obtained by immunizing Balb/c mice using human myeloma cells.

The feature of degrading an antibody is well known in the technical field in question; therefore, it would be easy for a person skilled in the art to produce antibody fragments by degrading the anti-HM1.24 antibodies that are indicated in documents 4 to 6.